These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 32579120)

  • 1. Elderly Medication Adherence Intervention Using the My Interventional Drug-Eluting Stent Educational App: Multisite Randomized Feasibility Trial.
    Boyd AD; Ndukwe CI; Dileep A; Everin OF; Yao Y; Welland B; Field J; Baumann M; Flores JD; Shroff A; Groo V; Dickens C; Doukky R; Francis R; Peacock G; Wilkie DJ
    JMIR Mhealth Uhealth; 2020 Jun; 8(6):e15900. PubMed ID: 32579120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. My Interventional Drug-Eluting Stent Educational App (MyIDEA): Patient-Centered Design Methodology.
    Boyd AD; Moores K; Shah V; Sadhu E; Shroff A; Groo V; Dickens C; Field J; Baumann M; Welland B; Gutowski G; Flores JD; Zhao Z; Bahroos N; Hynes DM; Wilkie DJ
    JMIR Mhealth Uhealth; 2015 Jul; 3(3):e74. PubMed ID: 26139587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short- and Midterm Adherence to Platelet P2Y12 Receptor Inhibitors After Percutaneous Coronary Intervention With Drug-Eluting Stents.
    Morita F; Wajngarten M; Katz M; Fernandes-Silva MM; Caixeta A; Franken M; Lemos PA; Pesaro AE
    J Cardiovasc Pharmacol Ther; 2020 Sep; 25(5):466-471. PubMed ID: 32419491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of Drug-Eluting Stents in Subjects With Peripheral Arterial Disease: Analysis From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
    Gupta R; Kirtane AJ; Ozan MO; Witzenbichler B; Rinaldi MJ; Metzger DC; Weisz G; Stuckey TD; Brodie BR; Mehran R; Ben-Yehuda O; Stone GW
    Circ Cardiovasc Interv; 2017 Mar; 10(3):. PubMed ID: 28288963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-Centered Tablet Application for Improving Medication Adherence after a Drug-Eluting Stent.
    Shah V; Dileep A; Dickens C; Groo V; Welland B; Field J; Baumann M; Flores JD; Shroff A; Zhao Z; Yao Y; Wilkie DJ; Boyd AD
    Front Public Health; 2016; 4():272. PubMed ID: 28018897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of 3- to 6-Month Versus 12-Month Dual Antiplatelet Therapy After Coronary Intervention Using the Contemporary Drug-Eluting Stents With Ultrathin Struts: The HOST-IDEA Randomized Clinical Trial.
    Han JK; Hwang D; Yang S; Park SH; Kang J; Yang HM; Park KW; Kang HJ; Koo BK; Hur SH; Kim W; Kim SY; Park SH; Han SH; Kim SH; Shin S; Kim YH; Park K; Lee N; Lee SJ; Kim JW; Kim HS
    Circulation; 2023 May; 147(18):1358-1368. PubMed ID: 36871230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Telephone contact to improve adherence to dual antiplatelet therapy after drug-eluting stent implantation.
    Rinfret S; Rodés-Cabau J; Bagur R; Déry JP; Dorais M; Larose E; Barbeau G; Gleeton O; Nguyen CM; Noël B; Proulx G; Roy L; Taillon I; De Larochellière R; Bertrand OF;
    Heart; 2013 Apr; 99(8):562-9. PubMed ID: 23434769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials.
    Giacoppo D; Matsuda Y; Fovino LN; D'Amico G; Gargiulo G; Byrne RA; Capodanno D; Valgimigli M; Mehran R; Tarantini G
    Eur Heart J; 2021 Jan; 42(4):308-319. PubMed ID: 33284979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial.
    Hahn JY; Song YB; Oh JH; Chun WJ; Park YH; Jang WJ; Im ES; Jeong JO; Cho BR; Oh SK; Yun KH; Cho DK; Lee JY; Koh YY; Bae JW; Choi JW; Lee WS; Yoon HJ; Lee SU; Cho JH; Choi WG; Rha SW; Lee JM; Park TK; Yang JH; Choi JH; Choi SH; Lee SH; Gwon HC;
    JAMA; 2019 Jun; 321(24):2428-2437. PubMed ID: 31237645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-platelet Regimen).
    Park KW; Kang SH; Park JJ; Yang HM; Kang HJ; Koo BK; Park BE; Cha KS; Rhew JY; Jeon HK; Shin ES; Oh JH; Jeong MH; Kim S; Hwang KK; Yoon JH; Lee SY; Park TH; Moon KW; Kwon HM; Chae IH; Kim HS
    JACC Cardiovasc Interv; 2013 Sep; 6(9):932-42. PubMed ID: 24050860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With Drug-Eluting Stents: 2-Year Results of a Prospective, Multicenter Registry Study.
    Stuckey TD; Kirtane AJ; Brodie BR; Witzenbichler B; Litherland C; Weisz G; Rinaldi MJ; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri EL; Gurbel PA; Mehran R; Généreux P; Ben-Yehuda O; Simonton CA; Stone GW;
    JACC Cardiovasc Interv; 2017 Aug; 10(16):1607-1617. PubMed ID: 28780034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized comparison of platinum chromium-based everolimus-eluting stents versus cobalt chromium-based Zotarolimus-Eluting stents in all-comers receiving percutaneous coronary intervention: HOST-ASSURE (harmonizing optimal strategy for treatment of coronary artery stenosis-safety & effectiveness of drug-eluting stents & anti-platelet regimen), a randomized, controlled, noninferiority trial.
    Park KW; Kang SH; Kang HJ; Koo BK; Park BE; Cha KS; Rhew JY; Jeon HK; Shin ES; Oh JH; Jeong MH; Kim S; Hwang KK; Yoon JH; Lee SY; Park TH; Moon KW; Kwon HM; Hur SH; Ryu JK; Lee BR; Park YW; Chae IH; Kim HS;
    J Am Coll Cardiol; 2014 Jul; 63(25 Pt A):2805-16. PubMed ID: 24814486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
    Feres F; Costa RA; Abizaid A; Leon MB; Marin-Neto JA; Botelho RV; King SB; Negoita M; Liu M; de Paula JE; Mangione JA; Meireles GX; Castello HJ; Nicolela EL; Perin MA; Devito FS; Labrunie A; Salvadori D; Gusmão M; Staico R; Costa JR; de Castro JP; Abizaid AS; Bhatt DL;
    JAMA; 2013 Dec; 310(23):2510-22. PubMed ID: 24177257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can phone-based motivational interviewing improve medication adherence to antiplatelet medications after a coronary stent among racial minorities? A randomized trial.
    Palacio AM; Uribe C; Hazel-Fernandez L; Li H; Tamariz LJ; Garay SD; Carrasquillo O
    J Gen Intern Med; 2015 Apr; 30(4):469-75. PubMed ID: 25500787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions.
    Mauri L; Kereiakes DJ; Normand SL; Wiviott SD; Cohen DJ; Holmes DR; Bangalore S; Cutlip DE; Pencina M; Massaro JM
    Am Heart J; 2010 Dec; 160(6):1035-41, 1041.e1. PubMed ID: 21146655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
    Yu J; Mehran R; Baber U; Ooi SY; Witzenbichler B; Weisz G; Rinaldi MJ; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri EL; Brodie BR; Stuckey TD; Maehara A; Xu K; Ben-Yehuda O; Kirtane AJ; Stone GW
    Circ Cardiovasc Interv; 2017 Feb; 10(2):. PubMed ID: 28193677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation of a public health programme: direct Clopidogrel administration by cardiology units in acute myocardial infarction].
    Pedrazzoli AG; Malnis D; Cattaneo S; Rovelli G; De Servi S; Klugman S; Marzegalli M; Russo AG
    Epidemiol Prev; 2016; 40(1):51-7. PubMed ID: 26951702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term Effects of P2Y12 Inhibitor Monotherapy After Percutaneous Coronary Intervention: 3-Year Follow-up of the SMART-CHOICE Randomized Clinical Trial.
    Choi KH; Park YH; Song YB; Park TK; Lee JM; Yang JH; Choi JH; Choi SH; Oh JH; Chun WJ; Jang WJ; Im ES; Jeong JO; Cho BR; Oh SK; Yun KH; Cho DK; Lee JY; Koh YY; Bae JW; Choi JW; Lee WS; Yoon HJ; Lee SU; Cho JH; Choi WG; Rha SW; Gwon HC; Hahn JY;
    JAMA Cardiol; 2022 Nov; 7(11):1100-1108. PubMed ID: 36169938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An mHealth Intervention to Improve Medication Adherence and Health Outcomes Among Patients With Coronary Heart Disease: Randomized Controlled Trial.
    Ni Z; Wu B; Yang Q; Yan LL; Liu C; Shaw RJ
    J Med Internet Res; 2022 Mar; 24(3):e27202. PubMed ID: 35262490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.